83_FR_24424 83 FR 24322 - Government-Owned Inventions; Availability for Licensing

83 FR 24322 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 102 (May 25, 2018)

Page Range24322-24322
FR Document2018-11255

The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Federal Register, Volume 83 Issue 102 (Friday, May 25, 2018) 
[Federal Register Volume 83, Number 102 (Friday, May 25, 2018)]
[Notices]
[Page 24322]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-11255]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Amy Petrik, Ph.D., 240-627-3721; 
[email protected]. Licensing information and copies of the U.S. patent 
applications listed below may be obtained by communicating with the 
indicated licensing contact at the Technology Transfer and Intellectual 
Property Office, National Institute of Allergy and Infectious Diseases, 
5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Middle East Respiratory Syndrome Coronavirus Antibodies

Description of Technology

    Middle East Respiratory Syndrome coronavirus (MERS-CoV) causes a 
highly lethal pulmonary infection with ~35% mortality. Currently there 
are no prophylactic measures or effective therapies. Inventors at the 
Vaccine Research Center of the National Institute of Allergy and 
Infectious Diseases have identified and developed neutralizing 
monoclonal antibodies (nMAbs) against the MERS-CoV. This invention 
describes antibodies that target the Spike (S) glycoprotein on the 
coronavirus surface, which mediates viral entry into host cells. These 
novel antibodies target different regions of the S protein, and when 
administered in combination, reduce the possibility of viral escape. In 
preclinical testing, these nMAbs have demonstrated potent protective 
effects, preventing death, viral replication in the lower airways and 
severe disease in challenge studies with mice. In addition, these nMAbs 
have potential application for use in assays for detecting MERS-CoV S 
protein in infected patients or animals.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications

    Monoclonal antibodies developed against multiple regions of the 
coronavirus spike protein have potential application in the prevention 
and treatment of MERS-CoV. There is also potential application for 
their use as a diagnostic tool of infection.

Competitive Advantages

     In vitro models, the combinations of antibodies have been 
demonstrated to be effective in reducing viral escape.
     In vivo data in animal models demonstrated a potent 
ability to control infection.
     Applicable in diagnostic assays.

Development Stage

     In vivo data available (animal)
    Inventors: Barney Graham (NIAID), Wing-Pui Kong (NIAID), Kayvon 
Modjarrad (NIAID), Lingshu Wang (NIAID), Wei Shi (NIAID), Michael 
Gordon Joyce (NIAID), Masaru Kanekiyo (NIAID), John Mascola (NIAID).
    Intellectual Property: HHS Reference No. E-239-2014, U.S. 
Provisional Patent Application Number 62/120,353 filed February 25, 
2015, PCT Patent Application PCT/US2016/019395 filed February 24, 2016, 
Europe Patent Application Number 16711059.2 filed February 24, 2016, 
South Korea Patent Application Number 10-2017-7027105 filed September 
25, 2017, Saudi Arabia Patent Application Number 5173382168 filed 
August 21, 2017, and U.S. Patent Application Number 15/553,466 filed 
August 24, 2017.
    Licensing Contact: Amy Petrik Ph.D., 240-627-3721; 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize MERS-CoV monoclonal antibodies. For 
collaboration opportunities, please contact Amy Petrik, Ph.D., 240-627-
3721; [email protected].

    Dated: May 14, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2018-11255 Filed 5-24-18; 8:45 am]
 BILLING CODE 4140-01-P

24322 Federal Register / Vol. 83, No. 102 / Friday, May 25, 2018 / Notices further develop, evaluate or monoclonal antibodies (nMAbs) against Infectious Diseases is seeking statements commercialize Epstein-Barr monoclonal the MERS-CoV. This invention of capability or interest from parties antibody technologies. For collaboration describes antibodies that target the interested in collaborative research to opportunities, please contact Dr. Amy Spike (S) glycoprotein on the further develop, evaluate or Petrik, 240–627–3721; amy.petrik@ coronavirus surface, which mediates commercialize MERS-CoV monoclonal nih.gov. viral entry into host cells. These novel antibodies. For collaboration Dated: May 10, 2018. antibodies target different regions of the opportunities, please contact Amy S protein, and when administered in Petrik, Ph.D., 240–627–3721; Suzanne M. Frisbie combination, reduce the possibility of amy.petrik@nih.gov. Deputy Director, Technology Transfer and Intellectual Property Office, National Institute viral escape. In preclinical testing, these Dated: May 14, 2018. of Allergy and Infectious Diseases. nMAbs have demonstrated potent Suzanne M. Frisbie, [FR Doc. 2018–11256 Filed 5–24–18; 8:45 am] protective effects, preventing death, Deputy Director, Technology Transfer and viral replication in the lower airways Intellectual Property Office, National Institute BILLING CODE 4140–01–P and severe disease in challenge studies of Allergy and Infectious Diseases. with mice. In addition, these nMAbs [FR Doc. 2018–11255 Filed 5–24–18; 8:45 am] DEPARTMENT OF HEALTH AND have potential application for use in BILLING CODE 4140–01–P HUMAN SERVICES assays for detecting MERS-CoV S protein in infected patients or animals. National Institutes of Health This technology is available for DEPARTMENT OF HEALTH AND licensing for commercial development HUMAN SERVICES Government-Owned Inventions; in accordance with 35 U.S.C. 209 and 37 Availability for Licensing CFR part 404, as well as for further National Institutes of Health development and evaluation under a AGENCY: National Institutes of Health, research collaboration. National Eye Institute; Amended Notice HHS. of Meeting ACTION: Notice. Potential Commercial Applications Notice is hereby given of a change in Monoclonal antibodies developed the meeting of the National Advisory SUMMARY: The invention listed below is against multiple regions of the owned by an agency of the U.S. Eye Council, June 14, 2018, 08:30 a.m. coronavirus spike protein have potential to June 14, 2018, 05:00 p.m., NIH, Government and is available for application in the prevention and licensing to achieve expeditious National Eye Institute, 5635 Fishers treatment of MERS-CoV. There is also Lane, Terrace Level Conference Rooms, commercialization of results of potential application for their use as a federally-funded research and Rockville, MD 20852 which was diagnostic tool of infection. published in the Federal Register on development. Foreign patent applications are filed on selected Competitive Advantages May 04, 2018, 83 FR 19791. This meeting is being amended to inventions to extend market coverage • In vitro models, the combinations of change the Open and Close times. The for companies and may also be available antibodies have been demonstrated to for licensing. Closed portion is now from 8:30 a.m. to be effective in reducing viral escape. 10:30 a.m. The Open portion is now FOR FURTHER INFORMATION CONTACT: • In vivo data in animal models from 10:45 a.m. to 3:00 p.m. The Amy Petrik, Ph.D., 240–627–3721; demonstrated a potent ability to control meeting is partially Closed to the public. amy.petrik@nih.gov. Licensing infection. information and copies of the U.S. • Applicable in diagnostic assays. Dated: May 21, 2018. patent applications listed below may be Natasha M. Copeland, Development Stage Program Analyst, Office of Federal Advisory obtained by communicating with the indicated licensing contact at the • In vivo data available (animal) Committee Policy. Technology Transfer and Intellectual Inventors: Barney Graham (NIAID), [FR Doc. 2018–11211 Filed 5–24–18; 8:45 am] Property Office, National Institute of Wing-Pui Kong (NIAID), Kayvon BILLING CODE 4140–01–P Allergy and Infectious Diseases, 5601 Modjarrad (NIAID), Lingshu Wang Fishers Lane, Rockville, MD 20852; tel. (NIAID), Wei Shi (NIAID), Michael 301–496–2644. A signed Confidential Gordon Joyce (NIAID), Masaru Kanekiyo DEPARTMENT OF HEALTH AND Disclosure Agreement will be required (NIAID), John Mascola (NIAID). HUMAN SERVICES to receive copies of unpublished patent Intellectual Property: HHS Reference No. E–239–2014, U.S. Provisional Patent National Institutes of Health applications. Application Number 62/120,353 filed SUPPLEMENTARY INFORMATION: National Institute of Allergy and February 25, 2015, PCT Patent Technology description follows. Infectious Diseases; Notice of Closed Application PCT/US2016/019395 filed Meetings Middle East Respiratory Syndrome February 24, 2016, Europe Patent Coronavirus Antibodies Application Number 16711059.2 filed Pursuant to section 10(d) of the February 24, 2016, South Korea Patent Federal Advisory Committee Act, as Description of Technology Application Number 10–2017–7027105 amended, notice is hereby given of the Middle East Respiratory Syndrome filed September 25, 2017, Saudi Arabia following meetings. coronavirus (MERS-CoV) causes a Patent Application Number 5173382168 The meetings will be closed to the amozie on DSK3GDR082PROD with NOTICES1 highly lethal pulmonary infection with filed August 21, 2017, and U.S. Patent public in accordance with the ∼35% mortality. Currently there are no Application Number 15/553,466 filed provisions set forth in sections prophylactic measures or effective August 24, 2017. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., therapies. Inventors at the Vaccine Licensing Contact: Amy Petrik Ph.D., as amended. The grant applications and Research Center of the National Institute 240–627–3721; amy.petrik@nih.gov. the discussions could disclose of Allergy and Infectious Diseases have Collaborative Research Opportunity: confidential trade secrets or commercial identified and developed neutralizing The National Institute of Allergy and property such as patentable material, VerDate Sep<11>2014 18:28 May 24, 2018 Jkt 241001 PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 E:\FR\FM\25MYN1.SGM 25MYN1


Document Created: 2018-05-25 02:13:03
Document Modified: 2018-05-25 02:13:03
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactAmy Petrik, Ph.D., 240-627-3721; [email protected] Licensing information and copies of the U.S. patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.
FR Citation83 FR 24322 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR